Fundamental Analysis of Gilead Sciences Inc - Growth / Value Index
GILD - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.486
Tsr Value Index - Poor Score of 26.56
Price to Book Ratio of 5.85 suggesting that it is very expensive
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 22.07 | 290.61 | 1087.02 % | |
| Price to Book | 5.86 | 7.25 | 19.98 % | 7.05 |
| Price to Sales | 4.83 | 4.85 | -4.27 % | |
| Enterprise Value to EBITDA Multiple | 16.90 | 93.99 | 531.09 % |
GILD - Profitability Highlights
Profitability Analysis
Excellent QoQ /QoQ FY EPS growth
During the past twelve months, the company has given a strong Return On Equity of 33.27%
All key Trailing Twelve Months Margin growing by 15 %
Steady Growth in EPS for last four quarters
Good Net Margin of 21.87% is achieved by the company
Low Earning Yield of 4.54 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 33.27 | 2.48 | -89.94 % | 9.96 |
| Return On Asset | 11.30 | 0.814 | -90.99 % | 3.52 |
| Net Profit Margin | 21.87 | 1.67 | -91.94 % | 27.68 |
| Operating Profit Margin | 39.72 | 5.78 | -82.21 % | 38.47 |
| EBITDA Margin | 31.70 | 5.78 | -85.07 % | 41.03 |
Highlights
| Market Cap | 137915 M |
| Enterprise Value | 154635 M |
| Price/Book TTM | 5.86 |
| Outstanding Share | 1240.81 M |
| Float/ Outstanding Share | 99.79% |
| Dividend Yield | 2.77 % |
Share Holding
Guru Numbers
| Price/Graham No | 2.67 |
| Peter Lynch Ratio | -4.15 |
| Piotroski F Score | 6.00 |
| Altman Z Score | 2.93 |
| Sloan Ratio | -0.117 |
| Peter Lynch Fair Value | 0 |
GILD - Growth Highlights
Growth Analysis
Tsr Growth Index - Very Poor Score of 7.57
Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 28862.00 M | 6.04 % | 6.21 % |
| Gross Profit | 17336.00 M | 99.62 % | 2.21 % |
| EBITDA | 9149.00 M | 84.17 % | 52.17 % |
| Net Profit | 6311.00 M | 91.45 % | 49.05 % |
| EPS | 5.04 | 91.58 % | NA |
GILD - Stability Highlights
Stability Analysis
Company financial liquidity has improved
Tsr Stability Index - Poor Score of 21.88
Interest Coverage of -1.13
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 1.38 | 25.81 % | 1.27 |
| Cash Ratio | 0.832 | 11.40 % | |
| Quick Ratio | 1.45 | 14.77 % | 1.15 |
| Shareholders Equity | 32.77 | -10.52 % | |
| Debt to EBITDA | 16.07 | 575.10 % |
Historical Valuation Ratios of Gilead Sciences Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Gilead Sciences Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Gilead Sciences Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Gilead Sciences Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)